Therapeutic strategies for laryngeal manifestations of gastroesophageal reflux disease

Journal of Clinical Gastroenterology

Volumn 47, Issue 3, 2013, Pages 195-204

  Yuksel, Elif S ^a   Vaezi, Michael F ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

laryngitis; reflux; treatment

Indexed keywords

ALGINIC ACID; AMITRIPTYLINE; ANTACID AGENT; ANTIHISTAMINIC AGENT; GABAPENTIN; PREGABALIN; PROTON PUMP INHIBITOR;

ALCOHOL CONSUMPTION; CLINICAL FEATURE; DIET; EXERCISE; GASTROESOPHAGEAL REFLUX; HUMAN; LARYNGOPHARYNGEAL REFLUX; LIFESTYLE MODIFICATION; OBESITY; PRIORITY JOURNAL; REVIEW; SLEEP; SMOKING CESSATION; STOMACH FUNDOPLICATION;

ANIMALS; ELECTRIC IMPEDANCE; ENDOSCOPY, DIGESTIVE SYSTEM; ESOPHAGEAL PH MONITORING; GASTROESOPHAGEAL REFLUX; HUMANS; LARYNGITIS; LARYNGOPHARYNGEAL REFLUX; LARYNGOSCOPY; PROTON PUMP INHIBITORS; SENSITIVITY AND SPECIFICITY;

EID: 84873893947     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e31827458f9     Document Type: Review

References (123)

1. Vaezi MF, Hicks DM, Abelson TI, et al. Laryngeal signs and symptoms and gastroesophageal reflux disease (GERD): a critical assessment of cause and effect association. Clin Gastroenterol Hepatol. 2003;1:333-344.
2. Koufman JA, Wiener GJ, Wallace CW, et al. Reflux laryngitis and its sequela. J Voice. 1988;2:78-79.
3. Gaynor EB. Otolaryngologic manifestations of gastroesophageal reflux. Am J Gastroenterol. 1991;86:801-808.
4. Graser A. Gastroesophageal reflux and laryngeal symptoms. Aliment Pharmacol Ther. 1994;8:265-272.
5. Koufman J, Sataloff RT, Toohill R. Laryngopharyngeal reflux: consensus conference report. J Voice. 1996;10:215-216.
6. Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope. 1991;101: 1-78.
7. Richter JE. Typical and atypical presentations of gastroesophageal reflux disease. The role of esophageal testing in diagnosis and management. Gastroenterol Clin North Am. 1996;25:75-102.
8. Toohill RJ, Kuhn JC. Role of refluxed acid in pathogenesis of laryngeal disorders. Am J Med. 1997;103:100S-106S.
9. Ward PH, Hanson DG. Reflux as an etiological factor of carcinoma of the laryngopharynx. Laryngoscope. 1998;98: 1195-1199.
10. Freije JE, Beatty TW, Campbell BH, et al. Carcinoma of the larynx in patients with gastroesophageal reflux. Am J Otolaryngol. 1996;17:386-390.
11. Morrison MD. Is chronic gastroesophageal reflux a causative factor in glottic carcinoma? Otolaryngol Head Neck Surg. 1988;99:370-373.
12. Vaezi MF, Qadeer MA, Lopez R, et al. Laryngeal cancer and gastroesophageal reflux disease: a case-control study. Am J Med. 2006;119:768-776.
13. Qadeer MA, Colabianchi N, Strome M, et al. Gastroesophageal reflux and laryngeal cancer: causation or association? A critical review. Am J Otolaryngol. 2006;27:119-128.
14. Rymer JAFD, Goutte M, Slaughter JC, et al. Economic burden of extraesophageal reflux disease. Gastroenterology. 2011;150:S136-S137.
15. Coffin L. The relationship of upper airway passages to diseases of gastrointestinal tract. Ann Otol Rhinol Laryngol. 1903;12:521-526.
16. Jackson CMS. Contact ulcer of larynx. Ann Otol Rhinol Laryngol. 1928;37-45.
17. Cherry J, Margulies SI. Contact ulcer of the larynx. Laryngoscope. 1968;78:1937-1940.
18. Vakil N, van Zanten SV, Kahrilas P, et al. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900-1920; quiz 1943.
19. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology. 2008;135:1383-1391, 1391 e1-5.
20. Locke GR III, Talley NJ, Fett SL, et al. Prevalence and clinical spectrum of gastroesophageal reflux: a populationbased study in Olmsted County, Minnesota. Gastroenterology. 1997;112:1448-1456.
21. el-Serag HB, Sonnenberg A. Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology. 1997;113:755-760.
22. Sontag SJ, O'Connell S, Khandelwal S, et al. Asthmatics with gastroesophageal reflux: long term results of a randomized trial of medical and surgical antireflux therapies. Am J Gastroenterol. 2003;98:987-999.
23. Hanson DG, Jiang JJ. Diagnosis and management of chronic laryngitis associated with reflux. Am J Med. 2000;108(suppl 4a):112S-119S.
24. Loughlin CJ, Koufman JA, Averill DB, et al. Acid-induced laryngospasm in a canine model. Laryngoscope. 1996;106: 1506-1509.
25. Adhami T, Goldblum JR, Richter JE, et al. The role of gastric and duodenal agents in laryngeal injury: an experimental canine model. Am J Gastroenterol. 2004;99:2098-2106.
26. Vaezi MF. Laryngitis: From the gastroenterologist's point of view. In: Vaezi MF, ed. Extraesophageal Reflux. San Diego, CA: Plural Publishing, Inc; 2009:37-47.
27. Altman KW, Prufer N, Vaezi MF. A review of clinical practice guidelines for reflux disease: toward creating a clinical protocol for the otolaryngologist. Laryngoscope. 2011;121:717-723.
28. Barry DW, Vaezi MF. Laryngopharyngeal reflux: more questions than answers. Cleve Clin J Med. 2010;77:327-334.
29. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723-1727.
30. Nilsson M, Johnsen R, Ye W, et al. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. JAMA. 2003;290:66-72.
31. Murray L, Johnston B, Lane A, et al. Relationship between body mass and gastro-oesophageal reflux symptoms: The Bristol Helicobacter Project. Int J Epidemiol. 2003;32: 645-650.
32. Aslam M, Slaughter JC, Goutte M, et al. Nonlinear relationship between body mass index and esophageal acid exposure in the extraesophageal manifestations of reflux. Clin Gastroenterol Hepatol. 2012;10:874-878.
33. Pandolfino JE, El-Serag HB, Zhang Q, et al. Obesity: a challenge to esophagogastric junction integrity. Gastroenterology. 2006;130:639-649.
34. Akiyama T, Yoneda M, Maeda S, et al. Visceral obesity and the risk of Barrett's esophagus. Digestion. 2011;83:142-145.
35. Lagergren J. Influence of obesity on the risk of esophageal disorders. Nat Rev Gastroenterol Hepatol. 2011;8:340-347.
36. Quitadamo P, Buonavolonta R, Miele E, et al. Total and abdominal obesity are risk factors for gastroesophageal reflux symptoms in children. J Pediatr Gastroenterol Nutr. 2012; 55:72-75.
37. Fraser-Moodie CA, Norton B, Gornall C, et al. Weight loss has an independent beneficial effect on symptoms of gastrooesophageal reflux in patients who are overweight. Scand J Gastroenterol. 1999;34:337-340.
38. Jacobson BC, Somers SC, Fuchs CS, et al. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med. 2006;354:2340-2348.
39. Anderson JW, Jhaveri MA. Reductions in medications with substantial weight loss with behavioral intervention. Curr Clin Pharmacol. 2010;5:232-238.
40. Kjellin A, Ramel S, Rossner S, et al. Gastroesophageal reflux in obese patients is not reduced by weight reduction. Scand J Gastroenterol. 1996;31:1047-1051.
41. Prachand VN, Alverdy JC. Gastroesophageal reflux disease and severe obesity: fundoplication or bariatric surgery? World J Gastroenterol. 2010;16:3757-3761.
42. Woodman G, Cywes R, Billy H, et al. Effect of adjustable gastric banding on changes in gastroesophageal reflux disease (GERD) and quality of life. Curr Med Res Opin. 2012;28:581-589.
43. Naef M, Mouton WG, Naef U, et al. Esophageal dysmotility disorders after laparoscopic gastric banding-an underestimated complication. Ann Surg. 2011;253:285-290.
44. Csendes A, Burgos AM, Smok G, et al. Effect of gastric bypass on Barrett's esophagus and intestinal metaplasia of the cardia in patients with morbid obesity. J Gastrointest Surg. 2006;10:259-264.
45. Nebel OT, Castell DO. Inhibition of the lower oesophageal sphincter by fat: a mechanism for fatty food intolerance. Gut. 1973;14:270-274.
46. Mangano M, Colombo P, Bianchi PA, et al. Fat and esophageal sensitivity to acid. Dig Dis Sci. 2002;47:657-660.
47. Pehl C, Pfeiffer A, Waizenhoefer A, et al. Effect of caloric density of a meal on lower oesophageal sphincter motility and gastro-oesophageal reflux in healthy subjects. Aliment Pharmacol Ther. 2001;15:233-239.
48. Penagini R. Fat and gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2000;12:1343-1345.
49. El-Serag HB, Satia JA, Rabeneck L. Dietary intake and the risk of gastro-oesophageal reflux disease: a cross sectional study in volunteers. Gut. 2005;54:11-17.
50. Fox M, Barr C, Nolan S, et al. The effects of dietary fat and calorie density on esophageal acid exposure and reflux symptoms. Clin Gastroenterol Hepatol. 2007;5:439-444.
51. Meyer JH, Lembo A, Elashoff JD, et al. Duodenal fat intensifies the perception of heartburn. Gut. 2001;49:624-628.
52. Feinle C, Christen M, Grundy D, et al. Effects of duodenal fat, protein or mixed-nutrient infusions on epigastric sensations during sustained gastric distension in healthy humans. Neurogastroenterol Motil. 2002;14:205-213.
53. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006;166: 965-971.
54. Feldman M, Barnett C. Relationships between the acidity and osmolality of popular beverages and reported postprandial heartburn. Gastroenterology. 1995;108:125-131.
55. Khoury RM, Camacho-Lobato L, Katz PO, et al. Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol. 1999;94:2069-2073.
56. Hamilton JW, Boisen RJ, Yamamoto DT, et al. Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid. Dig Dis Sci. 1988;33:518-522.
57. Harvey RF, Gordon PC, Hadley N, et al. Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis. Lancet. 1987;2:1200-1203.
58. Fletcher KC, Goutte M, Slaughter JC, et al. Significance and degree of reflux in patients with primary extraesophageal symptoms. Laryngoscope. 2011;121:2561-2565.
59. Hoppo T, Komatsu Y, Nieponice A, et al. Toward an improved understanding of isolated upright reflux: positional effects on the lower esophageal sphincter in patients with symptoms of gastroesophageal reflux. World J Surg. 2012;36:1623-1631.
60. Shay SS, Conwell DL, Mehindru V, et al. The effect of posture on gastroesophageal reflux event frequency and composition during fasting. Am J Gastroenterol. 1996;91: 54-60.
61. Duroux P, Bauerfeind P, Emde C, et al. Early dinner reduces nocturnal gastric acidity. Gut. 1989;30:1063-1067.
62. Piesman M, Hwang I, Maydonovitch C, et al. Nocturnal reflux episodes following the administration of a standardized meal. Does timing matter? Am J Gastroenterol. 2007; 102:2128-2134.
63. Avidan B, Sonnenberg A, Schnell TG, et al. Walking and chewing reduce postprandial acid reflux. Aliment Pharmacol Ther. 2001;15:151-155.
64. Nilsson M, Johnsen R, Ye W, et al. Lifestyle related risk factors in the aetiology of gastro-oesophageal reflux. Gut. 2004;53:1730-1735.
65. Kraus BB, Sinclair JW, Castell DO. Gastroesophageal reflux in runners. Characteristics and treatment. Ann Intern Med. 1990;112:429-433.
66. Kahrilas PJ, Gupta RR. The effect of cigarette smoking on salivation and esophageal acid clearance. J Lab Clin Med. 1989;114:431-438.
67. Smit CF, Copper MP, van Leeuwen JA, et al. Effect of cigarette smoking on gastropharyngeal and gastroesophageal reflux. Ann Otol Rhinol Laryngol. 2001;110:190-193.
68. Pehl C, Pfeiffer A, Wendl B, et al. Effect of smoking on the results of esophageal pH measurement in clinical routine. J Clin Gastroenterol. 1997;25:503-506.
69. Pehl C, Frommherz M, Wendl B, et al. Effect of white wine on esophageal peristalsis and acid clearance. Scand J Gastroenterol. 2000;35:1255-1259.
70. Bujanda L. The effects of alcohol consumption upon the gastrointestinal tract. Am J Gastroenterol. 2000;95:3374-3382.
71. Bor S, Bor-Caymaz C, Tobey NA, et al. Esophageal exposure to ethanol increases risk of acid damage in rabbit esophagus. Dig Dis Sci. 1999;44:290-300.
72. Rubinstein E, Hauge C, Sommer P, et al. Oesophageal and gastric potential difference and pH in healthy volunteers following intake of coca-cola, red wine, and alcohol. Pharmacol Toxicol. 1993;72:61-65.
73. Grande L, Manterola C, Ros E, et al. Effects of red wine on 24-hour esophageal pH and pressures in healthy volunteers. Dig Dis Sci. 1997;42:1189-1193.
74. Pehl C, Frommherz M, Wendl B, et al. Gastroesophageal reflux induced by white wine: the role of acid clearance and "rereflux". Am J Gastroenterol. 2002;97:561-567.
75. Mohammed I, Nightingale P, Trudgill NJ. Risk factors for gastro-oesophageal reflux disease symptoms: a community study. Aliment Pharmacol Ther. 2005;21:821-827.
76. Fackler WK, Ours TM, Vaezi MF, et al. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002;122:625-632.
77. Ours TM, Fackler WK, Richter JE, et al. Nocturnal acid breakthrough: clinical significance and correlation with esophageal acid exposure. Am J Gastroenterol. 2003;98: 545-550.
78. Khan M, Santana J, Donnellan C, et al. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev. 2007;2:CD003244.
79. Havas T, Huang S, Levy M, et al. Posterior pharyngolaryngitis: double-blind randomised placebo-controlled trial of proton pump inhibitor therapy. Aust J Otolaryngol. 1999;3:243-248.
80. Noordzij JP, Khidr A, Evans BA, et al. Evaluation of omeprazole in the treatment of reflux laryngitis: a prospective, placebo-controlled, randomized, double-blind study. Laryngoscope. 2001;111:2147-2151.
81. El-Serag HB, Lee P, Buchner A, et al. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol. 2001;96: 979-983.
82. Eherer AJ, Habermann W, Hammer HF, et al. Effect of pantoprazole on the course of reflux-associated laryngitis: a placebo-controlled double-blind crossover study. Scand J Gastroenterol. 2003;38:462-467.
83. Steward DL, Wilson KM, Kelly DH, et al. Proton pump inhibitor therapy for chronic laryngo-pharyngitis: a randomized placebo-control trial. Otolaryngol Head Neck Surg. 2004;131:342-350.
84. Wo JM, Koopman J, Harrell SP, et al. Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux. Am J Gastroenterol. 2006;101: 1972-1978. quiz 2169.
85. Vaezi MF, Richter JE, Stasney CR, et al. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope. 2006;116:254-260.
86. Reichel O, Dressel H, Wiederanders K, et al. Double-blind, placebo-controlled trial with esomeprazole for symptoms and signs associated with laryngopharyngeal reflux. Otolaryngol Head Neck Surg. 2008;139:414-420.
87. Fass R. Empirical trials in treatment of gastroesophageal reflux disease. Dig Dis. 2000;18:20-26.
88. Williams RB, Szczesniak MM, Maclean JC, et al. Predictors of outcome in an open label, therapeutic trial of high-dose omeprazole in laryngitis. Am J Gastroenterol. 2004;99: 777-785.
89. Klopocka M, Sinkiewicz A, Budzynski J, et al. Improvement in clinical course and laryngeal appearance in selected patients with chronic laryngitis after eight weeks of therapy with rabeprazole. Med Sci Monit. 2004;10:PI115-PI118.
90. Shaw GY, Searl JP. Laryngeal manifestations of gastroesophageal reflux before and after treatment with omeprazole. South Med J. 1997;90:1115-1122.
91. Swoger J, Ponsky J, Hicks DM, et al. Surgical fundoplication in laryngopharyngeal reflux unresponsive to aggressive acid suppression: a controlled study. Clin Gastroenterol Hepatol. 2006;4:433-441.
92. Qadeer MA, Phillips CO, Lopez AR, et al. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006;101:2646-2654.
93. Park W, Hicks DM, Khandwala F, et al. Laryngopharyngeal reflux: prospective cohort study evaluating optimal dose of proton-pump inhibitor therapy and pretherapy predictors of response. Laryngoscope. 2005;115:1230-1238.
94. Charbel S, Khandwala F, Vaezi MF. The role of esophageal pH monitoring in symptomatic patients on PPI therapy. Am J Gastroenterol. 2005;100:283-289.
95. Vaezi MFLR, Hicks D, Abelson T, et al. What is the optimal initial therapy duration for patients with suspected GERDrelated laryngitis? Gastroenterology. 2006;130:A140.
96. Koufman JA, Aviv JE, Casiano RR, et al. Laryngopharyngeal reflux: position statement of the committee on speech, voice, and swallowing disorders of the American Academy of Otolaryngology-Head and Neck Surgery. Otolaryngol Head Neck Surg. 2002;127:32-35.
97. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009;301:937-944.
98. Hirschowitz BI, Worthington J, Mohnen J. Vitamin B12 deficiency in hypersecretors during long-term acid suppression with proton pump inhibitors. Aliment Pharmacol Ther. 2008;27:1110-1121.
99. Bove MJ, Rosen C. Diagnosis and management of laryngopharyngeal reflux disease. Curr Opin Otolaryngol Head Neck Surg. 2006;14:116-123.
100. Dettmar PW, Hampson FC, Jain A, et al. Administration of an alginate based gastric reflux suppressant on the bioavailability of omeprazole. Indian J Med Res. 2006;123:517-524.
101. Dettmar PW, Hampson FC, Taubel J, et al. The suppression of gastro-oesophageal reflux by alginates. Int J Clin Pract. 2007;61:1654-1662.
102. Lindow SW, Regnell P, Sykes J, et al. An open-label, multicentre study to assess the safety and efficacy of a novel reflux suppressant (Gaviscon Advance) in the treatment of heartburn during pregnancy. Int J Clin Pract. 2003;57:175-179.
103. McGlashan JA, Johnstone LM, Sykes J, et al. The value of a liquid alginate suspension (Gaviscon Advance) in the management of laryngopharyngeal reflux. Eur Arch Otorhinolaryngol. 2009;266:243-251.
104. Weberg R, Berstad A. Symptomatic effect of a low-dose antacid regimen in reflux oesophagitis. Scand J Gastroenterol. 1989;24:401-406.
105. Grove O, Bekker C, Jeppe-Hansen MG, et al. Ranitidine and high-dose antacid in reflux oesophagitis. A randomized, placebo-controlled trial. Scand J Gastroenterol. 1985;20:457-461.
106. Simon B, Ravelli GP, Goffin H. Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 1996;10:441-446.
107. Herrera JL, Shay SS, McCabe M, et al. Sucralfate used as adjunctive therapy in patients with severe erosive peptic esophagitis resulting from gastroesophageal reflux. Am J Gastroenterol. 1990;85:1335-1338.
108. Ranchet G, Gangemi O, Petrone M. Sucralfate in the treatment of gravid pyrosis. G Ital Obstet Ginocol. 1990; 12:1-16.
109. Katz PO, Castell DO. Medical therapy of supraesophageal gastroesophageal reflux disease. Am J Med. 2000;108(suppl 4a):170S-177S.
110. Rosenow EC III. Persistent cough: causes and cures. Hosp Pract (Minneap). 1996;31:121-127; discussion 127-128.
111. Bastian RW, Vaidya AM, Delsupehe KG. Sensory neuropathic cough: a common and treatable cause of chronic cough. Otolaryngol Head Neck Surg. 2006;135: 17-21.
112. O'Connell F, Thomas VE, Pride NB, et al. Capsaicin cough sensitivity decreases with successful treatment of chronic cough. Am J Respir Crit Care Med. 1994;150:374-380.
113. Morrison M, Rammage L, Emami AJ. The irritable larynx syndrome. J Voice. 1999;13:447-455.
114. Amin MR, Koufman JA. Vagal neuropathy after upper respiratory infection: a viral etiology? Am J Otolaryngol. 2001;22:251-256.
115. Altman KW, Simpson CB, Amin MR, et al. Cough and paradoxical vocal fold motion. Otolaryngol Head Neck Surg. 2002;127:501-511.
116. Lee B, Woo P. Chronic cough as a sign of laryngeal sensory neuropathy: diagnosis and treatment. Ann Otol Rhinol Laryngol. 2005;114:253-257.
117. Mintz S, Lee JK. Gabapentin in the treatment of intractable idiopathic chronic cough: case reports. Am J Med. 2006; 119:e13-e15.
118. Halum SL, Sycamore DL, McRae BR. A new treatment option for laryngeal sensory neuropathy. Laryngoscope. 2009;119:1844-1847.
119. LaRoche SM, Helmers SL. The new antiepileptic drugs: clinical applications. JAMA. 2004;291:615-620.
120. Klaus A, Swain JM, Hinder RA. Laparoscopic antireflux surgery for supraesophageal complications of gastroesophageal reflux disease. Am J Med. 2001;111(suppl 8A): 202S-206S.
121. So JB, Zeitels SM, Rattner DW. Outcomes of atypical symptoms attributed to gastroesophageal reflux treated by laparoscopic fundoplication. Surgery. 1998;124:28-32.
122. Francis DO, Goutte M, Slaughter JC, et al. Traditional reflux parameters and not impedance monitoring predict outcome after fundoplication in extraesophageal reflux. Laryngoscope. 2011;121:1902-1909.
123. Wetscher GJ, Glaser K, Gadenstaetter M, et al. The effect of medical therapy and antireflux surgery on dysphagia in patients with gastroesophageal reflux disease without esophageal stricture. Am J Surg. 1999;177:189-192.